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Onset is usually sudden with symmetrical articular involvement of both small and large joints, occurrence of solid skin nodules,
and rapid progression. Treatment is generally unrewarding. Here we report a severe and disabling case of FR responding favorably
to inﬂiximab therapy. After 32 weeks of continuous treatment, skin lesions dramatically improved and arthropathy partially
regressed.
Copyright © 2009 Ricardo Romiti et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Fibroblastic rheumatism (FR) is a rare disease of unknown
cause, initially described by Chaouat et al. in 1980.
The clinical picture of FR consists of skin nodules and
polyarthropathy with ﬂexion contractures of the ﬁngers.
Histological and immunohistochemical ﬁndings suggest that
FR should be included in the group of ﬁbromatoses. Our
group recently reported a case of FR with exuberant clinical
ﬁndings [1]. The patient was a 40-year-old man that pre-
sented with a 3-month history of cutaneous nodules. After
a few weeks, his skin acquired a severe sclerodermoid aspect
and signiﬁcant impairment resulted. Magnetic resonance of
the hands showed tenosynovitis of the ﬂexors, synovitis of
the metacarpophalangeal joints, and osteoarthritis of the
thumbs. Diagnosis of FR was based established on clinical
and pathological ﬁndings.
The patient was treated with prednisone (0.4mg/kg/day)
with mild cutaneous improvement. Due to progressive wors-
ening of his articular deformities, the dose of prednisone was
increased to 1.0mg/kg/day and methotrexate, 25mg/week,
was added. After 6 months, as no response was noted, the
TNF-alpha inhibitor, inﬂiximab, was started. Therapeutic
regimen consisted of inﬂiximab, 3.0mg/kg, in combination
with methotrexate—the same regimen used for treating
rheumatoid arthritis. After the ﬁrst three doses of inﬂiximab
at weeks 0, 2, and, 6, signiﬁcant reduction of nodules could
be observed. After 22 weeks of maintenance treatment,
skin ﬁbrosis decreased and was accompanied by moderate
improvement of joint mobility (Figures 1(a) and 1(b)).
Additionally, the patient could now perform several manual
activities that were impossible before. After an additional 10-
week treatment period, clinical response persisted and no
side-eﬀects were reported.
FR is acknowledged as very diﬃcult to treat. Ther-
apeutic modalities have included prednisone, colchicine,
interferon, penicillamine, methotrexate, and nonsteroidal
anti-inﬂammatory drugs, with mostly poor results.
TNF-alpha is a proinﬂammatory cytokine released by
macrophages, monocytes, and T lymphocytes as well as
many tissue-speciﬁc cell types including keratinocytes and
dendritic cells. The clinical eﬀectiveness of the TNF-alpha
inhibitor, inﬂiximab, in the treatment of diﬀerent inﬂam-
matory disorders has been demonstrated in several studies.
Although psoriasis remains the only condition in derma-
tology for which the use of biologic immunomodulators
has been approved, diﬀerent disorders have been reported
to favorably respond to anti-TNF treatment, including
hidradenitis suppurative, pyoderma gangrenosum, as well
as the noninfectious granulomatous diseases, among others
[2]. It is known that TNF alpha participates in activation
of vascular endothelium, regulation of immune response,
and metabolism of the connective tissue by modulation of
ﬁbroblastic function. Blockage of TNF alpha could possibly
explain partial regression of sclerodermoid alterations in
FR treated with inﬂiximab. Our experience suggests that2 Dermatology Research and Practice
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Figure 1: (a) Fibroblastic rheumatism before treatment. (b)
Improvement after 22 weeks, showing visible reduction of all
lesions.
the spectrum of disorders responding favorably to anti-TNF
agents may further include disabling FR. Other reports are
necessary to deﬁnitely conﬁrm the eﬃcacy of this novel
therapeutic indication of inﬂiximab.
References
[1] N. Kluger, A. Dumas-Tesici, D. Hamel, N. Brousse, and S.
Fraitag, “Fibroblastic rheumatism: ﬁbromatosis rather than
non-Langerhanscellhistiocytosis,”JournalofCutaneousPathol-
ogy. In press.
[2] I. M. L. Marconi, M. C. Rivitti-Machado, M. N. Sotto,
and M. M. S. Nico, “Fibroblastic rheumatism,” Clinical and
Experimental Dermatology, vol. 34, no. 1, pp. 29–32, 2009.